Grants and Giving
This grant funds educational initiatives that equip clinicians to improve screening, diagnosis, and management of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM).
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal, RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; actual funding may be less than requested.
Summary: Supports independent educational initiatives to advance clinical decision-making and improve outcomes in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only organizations (not individuals) may apply; proposals must be submitted via the Alnylam grant portal.
Description
Alnylam Pharmaceuticals is soliciting proposals for independent educational projects that address unmet needs in clinical decision-making for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). This opportunity—RFP ALNY-RFP-TTR-13—focuses on programs that equip clinicians with actionable knowledge, tools, and frameworks to improve the screening, diagnosis, monitoring, and management of ATTR-CM. The RFP encourages evidence-based, practical approaches that can be implemented in real-world clinical settings, with priority given to initiatives targeting gaps in early recognition, treatment, disease monitoring, and multidisciplinary care.
